EMEA-000876-PIP03-14-M05 - paediatric investigation plan
Eculizumab
PIPHuman
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com
Tel: +33 147100615
P/0514/2020 : EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP03-14-M05)